Asymmetric dimethylarginine (ADMA) as a cardiovascular risk factor in end-stage renal disease (ESRD)

European Journal of Clinical Pharmacology

Volumn 62, Issue 1, 2006, Pages 131-135

  Zoccali, Carmine ^a   Mallamaci, Francesca ^a   Tripepi, Giovanni ^a  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

Author keywords

ADMA; Cardiovascular risk; Dialysis

Indexed keywords

N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE INHIBITOR; NORADRENALIN; NITRIC OXIDE SYNTHASE;

ATHEROSCLEROSIS; BLOOD VESSEL DIAMETER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; COHORT ANALYSIS; CONFERENCE PAPER; DIALYSIS; HEART LEFT VENTRICLE MASS; HEART VENTRICLE HYPERTROPHY; HUMAN; INTIMA; KIDNEY FAILURE; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; DISEASE ASSOCIATION; ENDOTHELIUM; IN VIVO STUDY;

EID: 33344470216     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-005-0022-x     Document Type: Conference Paper

References (25)

1. Levey AS (1998) Controlling the epidemic of cardiovascular disease in chronic renal disease: where do we start?. Am J Kidney Dis 32[Suppl 3]:S5-S13
2. Zoccali C, Mallamaci F, Tripepi G (2003) Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int 85[Suppl]:S105-S110
3. Zoccali C, Mallamaci F, Tripepi G (2004) Novel cardiovascular risk factors in end-stage renal disease. J Am Soc Nephrol 15[Suppl 1]:S77-S80
4. Zoccali C, Mallamaci F, Parlongo S, Cutrupi SP, Benedetto FA, Tripepi G, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Stancanelli B, Malatino LS (2002) Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 105:1354-1359
5. Widlansky ME, Gokce N, Keaney JF Jr, Vita JA (2003) The clinical implications of endothelial dysfunction. J Am Coll Cardiol 42:1149-1160
6. Mancia G (2001) Clinical applications of methods for assessing the autonomic nervous system. Ital Heart J 28[Suppl]:823-830
7. Hijmering ML, Stroes ES, Olijhoek J, Hutten BA, Blankestijn PJ, Rabelink TJ (2002) Sympathetic activation markedly reduces endothelium-dependent, flow-mediated vasodilation. J Am Coll Cardiol 39:683-688
8. Cooke JP (2000) Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 20:2032-2037
9. Vallance P, Leone A, Calver A, Collier J, Moncada S (1992) Accumulation of an endogenous inhibitor of NO synthesis in chronic renal failure. Lancet 339:572-575
10. Kielstein JT, Böger RH, Bode-Böger SM, Schäffer J, Barbey M, Koch KM, Frölich JC (1999) Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 10:594-600
11. Zoccali C, Benedetto FA, Maas R, Mallamaci F, Tripepi G, Malatino LS, Böger RH (2002) Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol 13:490-496
12. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T (1999) Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 99:1141-1146
13. Perticone F, Maio R, Ceravolo R, Cosco C, Cloro C, Mattioli PL (1999) Relationship between left ventricular mass and endothelium-dependent vasodilation in never-treated hypertensive patients. Circulation 99:1991-1996
14. London GM, Guerin AP, Marchais SJ, Pannier B, Safar ME, Day M, Metivier F (1996) Cardiac and arterial interactions in end-stage renal disease. Kidney Int 50:600-608
15. Benedetto FA, Mallamaci F, Tripepi G, Zoccali C (2001) Prognostic importance of ultrasonographic measurement of carotid intima media thickness in dialysis patients. J Am Soc Nephrol 12:2458-2464
16. Pannier B, Guerin AP, Marchais SJ, Metivier F, Safar ME, London GM (2000) Postischemic vasodilation, endothelial activation, and cardiovascular remodeling in end-stage renal disease. Kidney Int 57:1091-1099
17. Zoccali C, Mallamaci F, Maas R, Benedetto FA, Tripepi G, Malatino LS, Cataliotti A, Bellanuova I, Böger RH (2002) Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 62:339-345
18. Sladek T, Gerova M, Znojil V, Devat L (1996) Morphometric characteristics of cardiac hypertrophy induced by long-term inhibition of NO synthase. Physiol Res 45:335-338
19. Kuhlencordt PJ, Gyurko R, Han F, Scherrer-Crosbie M, Aretz TH, Hajjar R, Picard MH, Huang PL (2001) Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. Circulation 104:448-454
20. Zoccali C, Bode-Böger SM, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frölich JC, Böger RH (2001) Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358:2113-2117
21. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, Vallance P (2003) Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 23:1455-1459
22. Kielstein JT, Impraim B, Simmel S, Bode-Böger SM, Tsikas D, Frölich JC, Hoeper MM, Haller H, Fliser D (2004) Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 109:172-177
23. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C (2005) Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol (in press)
24. Fliser D, Kronenberg F, Kielstein JT, Morath C, Bode-Böger SM, Haller H, Ritz E (2005) Asymmetric dimethylarginine and progression of chronic kidney disease: The mild to moderate kidney disease study. J Am Soc Nephrol (in press)
25. Mallamaci F, Tripepi G, Maas R, Malatino L, Böger RH, Zoccali C (2004) Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. J Am Soc Nephrol 15:435-441